Compare ST & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ST | TVTX |
|---|---|---|
| Founded | 1916 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.3B |
| IPO Year | 2009 | 2013 |
| Metric | ST | TVTX |
|---|---|---|
| Price | $42.60 | $51.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $53.30 | ★ $75.21 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $3,704,500,000.00 | N/A |
| Revenue This Year | $4.43 | $47.65 |
| Revenue Next Year | $4.23 | $49.39 |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.16 | $22.59 |
| 52 Week High | $53.89 | $68.73 |
| Indicator | ST | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 27.19 |
| Support Level | $40.44 | $41.75 |
| Resistance Level | $43.84 | $59.93 |
| Average True Range (ATR) | 1.02 | 2.17 |
| MACD | 0.08 | -0.78 |
| Stochastic Oscillator | 54.24 | 4.96 |
Sensata Technologies is a global supplier of sensors and electrical protection for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. It also sells electrical protection products, like contactors and relays. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.